Abstracts tagged "meta-analysis"

Abstract Number: 367 • 2015 ACR/ARHP Annual Meeting
Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Xerxes Pundole¹, Maria A. Lopez-Olivo², Hira Cheema³, Gabriela Sanchez Petitto⁴, Maria E. Suarez-Almazor⁵ and Huifang Lu⁶, ¹General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Texas Tech Odessa, Odessa, TX, ⁴The University of Texas, Health Science Center, Houston, TX, ⁵The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁶General Internal Medicine, AT &EC, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: The main goal of our study was to evaluate the efficacy and safety of bisphosphonates and/or general preventive strategies in the prevention and treatment…
Abstract Number: 439 • 2015 ACR/ARHP Annual Meeting
Progression of Radiographic Joint Destruction in Patients with Rheumatoid Arthritis Treated with a Biologic Agent in Combination with Methotrexate Versus a Biologic Alone: A Systematic Review and Meta-Analysis of Randomized Trials
Tanja Schjødt Jørgensen¹, Simon Tarp¹, Daniel E. Furst², Anna Døssing¹, Peter C. Taylor³, Henning Bliddal¹ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom
Background/Purpose : One of the frequently claimed advantages of biologic agents is their potential to arrest radiographic progression. The ability of disease-modifying antirheumatic drugs (DMARDs;…
Abstract Number: 835 • 2015 ACR/ARHP Annual Meeting
A Meta-Analysis to Determine If the Prevalence of Scleroderma Renal Crisis Decreasing with Time
Matthew Turk¹ and Janet E. Pope², ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease with increased mortality from various internal organ involvement. Scleroderma renal crisis (SRC) usually occurs…
Abstract Number: 1041 • 2015 ACR/ARHP Annual Meeting
Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Dmards for Rheumatoid Arthritis: A Cochrane Systematic Review and Network Meta-Analysis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, George A. Tomlinson⁴, Deborah Marshall⁵, Daniel Devoe⁵ and Claire Bombardier⁶, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare methotrexate based disease-modifying anti-rheumatic drug (DMARD) treatments for rheumatoid arthritis in patients naïve to or after an inadequate response (IR) to methotrexate. …
Abstract Number: 2433 • 2014 ACR/ARHP Annual Meeting
Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac for Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Fabiola Atzeni^1,2, Alessandra Monguzzi³, Elisabetta Grillo³, Luigi Lanata³ and Piercarlo Sarzi-Puttini², ¹V Giovanni Battista Grassi 74, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ²Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ³Medical Department, Dompé SpA, Milan, Italy
Background/Purpose: Patients with rheumatic diseases, including rheumatoid arthritis (RA), describe symptoms such as pain and stiffness as important factors affecting their quality of life. The…
Abstract Number: 2443 • 2014 ACR/ARHP Annual Meeting
A New Meta-Analysis on Safety of Ketoprofen Vs Ibuprofen and Diclofenac: Risk and Benefit of Nsaids Beyond Efficacy Meta-Analysis
P. Sarzi-Puttini¹, F. Atzeni¹, Luigi Lanata², Alessandra Monguzzi² and Michela Bagnasco², ¹Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²Medical Department, Dompé SpA, Milan, Italy
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for management of mild-to-moderate pain, chronic inflammatory and degenerative joint diseases. Among NSAIDs, ketoprofen, ibuprofen and diclofenac…
Abstract Number: 2420 • 2014 ACR/ARHP Annual Meeting
Quality Assessment of Controlled Trials Evaluating Chinese Herbal Medicine in Patients with Rheumatoid Arthritis: a Systematic Review
Xin Pan^1,2, Maria A. Lopez-Olivo², Pratibha Nayak³ and Maria E. Suarez-Almazor⁴, ¹Department of Rheumatology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Chinese herbal medicine (CHM) is a mainstay in the treatment of rheumatoid arthritis (RA) in China. We conducted a systematic review to appraise the…
Abstract Number: 2369 • 2014 ACR/ARHP Annual Meeting
Management of Perioperative Tumor Necrosis -á Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis
Susan M. Goodman¹, Indu Menon², Rie Smethurst³, Paul Christos⁴ and Vivian P. Bykerk¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, NY, NY, ³Education - Academic Training, Hospital for Special Surgery, NY, NY, ⁴Healthcare Policy and Research, Weill Cornell Medical College, NY, NY
Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…
Abstract Number: 2370 • 2014 ACR/ARHP Annual Meeting
Management of Perioperative Tumor Necrosis Factor α Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis
Susan M. Goodman¹, Indu Menon², Rie Smethurst³, Paul Christos⁴ and Vivian P. Bykerk¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, NY, NY, ³Education - Academic Training, Hospital for Special Surgery, NY, NY, ⁴Healthcare Policy and Research, Weill Cornell Medical College, NY, NY
Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…
Abstract Number: 1074 • 2014 ACR/ARHP Annual Meeting
A Meta-Analysis of the Risk of Venous Thromboembolism in Inflammatory Rheumatic Diseases
Jason J Lee¹ and Janet E. Pope², ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²St Joseph Health Care, London, ON, Canada
Background/Purpose: We performed a meta-analysis investigating the risk of developing deep vein thrombosis (DVT) and/or pulmonary embolisms (PE) in patients with inflammatory arthritis, vasculitis, and…
Abstract Number: 875 • 2014 ACR/ARHP Annual Meeting
Treatment-Related Outcomes in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Pooled Analysis of 12 Randomized Controlled Trials
Rennie L. Rhee¹, Nicole B. Gabler², Amy Praestgaard², Peter A. Merkel³ and Steven M. Kawut⁴, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Pulmonary and Critical Care, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Recent studies have shown that therapies for pulmonary arterial hypertension (PAH) improve exercise capacity, but subgroup analyses suggest that these therapies may be less…
Abstract Number: 747 • 2014 ACR/ARHP Annual Meeting
Systemic Sclerosis Patients with Antitopoisomerase Antibodies Showed Significant Association with CCR6 Polymorphisms
Javier Martin¹, Eguzkine Ochoa², Jose Ezequiel Martin¹, Shervin Assassi³, Lorenzo Beretta⁴, Patricia Carreira⁵, Carmen Pilar Simeon⁶, Eugénie Koumakis⁷, Philippe Dieude⁸, Yannick Allanore⁹, Francisco J. García-Hernández¹⁰, Gerard Espinosa¹¹, Ivan Castellvi Barranco¹², Luis Trapiella¹³, Luis Rodriguez Rodriguez¹⁴, Miguel A González-Gay¹⁵, María-Victoria Egurbide¹⁶, Luis Saez¹⁷, José Luis Callejas¹⁸, JA Vargas-Hitos¹⁹, Nicolas Hunzelmann²⁰, Gabriela Riemekasten²¹, Torsten Witte²², Jörg HW Distler²³, Alexander Kreuter²⁴, Claudio Lunardi²⁵, Alessandro Santaniello²⁶, Filemon K. Tan³, Frank C. Arnett³, Paul Shiels²⁷, Ariane L. Herrick²⁸, Jane Worthington²⁹, Madelon C. Vonk³⁰, Bobby P.C. Koeleman³¹, T.R.D.J. Radstake³² and Maureen Mayes³³, ¹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ²Immunology, Instituto de Parasitología y Biomedicina Lopez Neyra (IPBLN-CSIC), Granada, Spain, ³Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴Via Francesco Sforza 28, Ospedale Maggiore Policlinico, Milano, Italy, ⁵Hospital Universitario 12 de Octubre, Department of Rheumatology, Madrid, Spain, ⁶Servicio de Medicina Interna, Hospital Valle de Hebron, Barcelona, Spain, ⁷Rheumatology A department, Cochin Hospital, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁸Rhumatologie, Hopital Bichat Claude Bernard, Paris, France, ⁹Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, ¹⁰Internal Medicine, Hospital Virgen del Rocío, Sevilla, Spain, ¹¹Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, ¹²Hosp. De Sta. Creu i S. Pau, Vilafranca del Pened, Spain, ¹³Department of Internal Medicine,, Hospital Universitario Central de Asturias, Asturias, Spain, ¹⁴Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ¹⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ¹⁶Autoimmune Disease Research Unit, Service of Internal Medicine,, Hospital de Cruces, UPV/EHU, Barakaldo, Spain, Barakaldo, Spain, ¹⁷Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, Hospital Miguel Servet, Zaragoza, Spain, ¹⁸Internal Medicine, Hospital Clínico San Cecilio, Granada, Spain, ¹⁹Internal Medicine, Hospital Universitario Virgen de las Nieves, Granada, Spain, ²⁰Department of Dermatology, University of Cologne, Cologne, Germany, ²¹Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, ²²Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ²³Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²⁴Department of Dermatology, Venereology, and Allergologie, HELIOS St. Elisabeth Hospital, Oberhausen, Germany, ²⁵Department of Medicine, Università degli Studi di Verona, Verona, Italy, ²⁶Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²⁷University of Glasgow, Glasgow, United Kingdom, ²⁸Musculoskeletal Research Group, School of Translational Medicine, Manchester Academic Health Science Centre, Salford Royal Hospital, University of Manchester., Salford, United Kingdom, ²⁹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ³⁰Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³¹Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ³²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³³Internal Medicine/Rheumatology, University of TX Health Science Center -Houston, Houston, TX
Background/Purpose: Systemic sclerosis (SSc), also known as scleroderma, is an inflammatory autoimmune disease characterized by fibrosis of the skin and internal organs, vascular damage and…
Abstract Number: 673 • 2014 ACR/ARHP Annual Meeting
A Comparison of Rheumatoid Arthritis and Systemic Lupus Erythematosus Trial Design: Ways to Improve Positive Trials in Systemic Lupus Erythematosus
Amy Miles¹ and Janet E. Pope², ¹Medicine, University of Western Ontario and U of Toronto, London, ON, Canada, ²St Joseph Health Care, London, ON, Canada
Background/Purpose: Recent SLE RCTs were examined and compared to rheumatoid arthritis (RA) RCT to suggest modifications to SLE RCTs that could improve the future success…
Abstract Number: 477 • 2014 ACR/ARHP Annual Meeting
Leflunomide Use Is Not Associated with an Increased Risk of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials
Richard Conway¹, Candice Low², Robert J. Coughlan¹, Martin O'Donnell³ and John J. Carey¹, ¹Rheumatology, Galway University Hospitals, Galway, Ireland, ²Medicine, St. James Hospital, Dublin, Ireland, ³Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Background/Purpose Leflunomide is an effective treatment for rheumatoid arthritis. An association between pulmonary adverse events, in particular interstitial lung disease, and leflunomide use has been…
Abstract Number: 2772 • 2014 ACR/ARHP Annual Meeting
The Use of Imaging in the Diagnosis of Polymyalgia Rheumatica: Systematic Literature Review and Meta-Analysis
Sarah Mackie¹, Gouri Koduri², Catherine L. Hill^3,4, Andrew Hutchings⁵, Richard J. Wakefield⁶, Bhaskar Dasgupta⁷ and Jeremy Wyatt⁸, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ²Rheumatology, York Teaching Hospital NHS Foundation Trust, York, United Kingdom, ³Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia, ⁴Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁵Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁶NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷Department of Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁸Leeds Insitute of Health Sciences, University of Leeds, Leeds, United Kingdom
Background/Purpose ACR/EULAR provisional classification criteria for polymyalgia rheumatica (PMR) incorporate musculoskeletal ultrasound of shoulder and hip (bursitis and synovitis given equal weight). Our objective was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.